BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, reported yesterday its financial results for the quarter ended 31 October 2018.

The company reported total operating expenses at USD4.4m for the third quarter ended 31 October 2018 with total operating expenses of USD3.7m in the prior fiscal year's third quarter.

The firm posted net loss for the quarter ended 31 October 2018 at USD4.4m or USD0.02 per share compared with a net loss of USD3.7m or USD0.05 per share in the same period in 2017.

The company stated that during the quarter, newly appointed BioPharmX president and CEO Dr David S Tierney commenced a strategic review of the business and took steps to streamline strategy and focus on the company's core products to maximise shareholder value.